tak-906
Small moleculeexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 26, 2017 (NCT03161405)
Timeline
Indications
Mechanism of action
- Dopamine D3 receptorINHIBITOR
DRD3 inhibitor
- Dopamine D2 receptorINHIBITOR
DRD2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tak-906
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04831502 | Phase 1 | Apr 2, 2021 | Takeda |
| NCT04454918 | Phase 1 | Jul 30, 2020 | Millennium Pharmaceuticals |
| NCT04121078 | Phase 1 | Oct 15, 2019 | Millennium Pharmaceuticals |
| NCT03849690 | Phase 1 | Feb 27, 2019 | Millennium Pharmaceuticals |
| NCT03544229 | Phase 2 | Oct 12, 2018 | Millennium Pharmaceuticals, Takeda |
| NCT03268941 | Phase 1 | Sep 26, 2017 | Millennium Pharmaceuticals |
| NCT03237156 | Phase 1 | Aug 4, 2017 | Takeda |
| NCT03161405 | Phase 1 | May 26, 2017 | Millennium Pharmaceuticals, Takeda |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Millennium Pharmaceuticals | For profit | 6 | 6 | 2 | 2017 |
| Takeda | For profit | 4 | 2 | 2 | 2017 |
2 organizations
Page 1 / 1